XML 65 R30.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stock-based Compensation (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
Stock option activity for the three months ended March 31, 2024 is as follows (in thousands, except share and per share data):
Number of
Shares
Underlying
Outstanding
Options		Weighted-
Average Exercise
Price per Share		Weighted-
Average
Remaining
Contractual
Term (in years)		Aggregate
Intrinsic
Value
Outstanding—December 31, 20231,871,649 $7.36 6.71$5,160 
Options exercised(54,374)1.92 
Options cancelled(6,403)16.90 
Outstanding—March 31, 20241,810,872 $7.49 6.47$6,135 
Vested and expected to vest—March 31, 20241,810,872 $7.49 6.47$6,135 
Exercisable—March 31, 20241,578,366 $7.42 6.46$5,423 
Schedule of Stock Options Outstanding and Exercisable
The following table summarizes information about stock options outstanding and exercisable at March 31, 2024.
Options OutstandingOptions
Exercisable
Exercise
Price		Options
Outstanding		Weighted
Average
Remaining
Contractual
Life (Years)
$1.85 231,119 6.29222,579 
2.13 814,027 6.52700,364 
14.22 752,408 6.50642,679 
$52.40 13,318 5.6612,744 
1,810,872 1,578,366 
Schedule of Nonvested Restricted Stock Units Activity
A summary of RSU activity is as follows:
Number of
Shares		Weighted Average
Grant Date Fair
Value (per share)
Unvested—December 31, 20233,074,939 $13.19 
Granted193,894 7.91 
Canceled(65,574)12.58 
Vested(759,919)10.53 
Unvested—March 31, 20242,443,340 $13.62 
Schedule of Nonvested Restricted Stock Awards Activity
A summary of RSA activity is as follows:
Number of
Shares		Weighted Average
Grant Date Fair
Value (per share)
Unvested—December 31, 2023380,383 $15.30 
Granted533,601 7.94 
Vested(168,271)12.66 
Unvested—March 31, 2024745,713 $10.63 
Schedule of Stock-based Compensation
The Company recognized stock-based compensation expense for all share-based awards in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):
Three Months Ended March 31,
20242023
Cost of revenue$913 $774 
Research and development4,188 7,505 
Sales and marketing1,400 2,881 
General and administrative2,903 10,620 
Total stock-based compensation$9,404 $21,780 
The following table summarizes stock-based compensation expense by award type (in thousands):
Three Months Ended March 31,
20242023
RSUs$6,809 $16,330 
Stock Options1,530 2,005 
Employee stock purchase plan505 184 
RSAs560 3,261 
Total stock-based compensation$9,404 $21,780